These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 35669787)

  • 1. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Rickeard T; Gallagher E; Gower C; Kall M; Groves N; O'Connell AM; Simons D; Blomquist PB; Zaidi A; Nash S; Iwani Binti Abdul Aziz N; Thelwall S; Dabrera G; Myers R; Amirthalingam G; Gharbia S; Barrett JC; Elson R; Ladhani SN; Ferguson N; Zambon M; Campbell CNJ; Brown K; Hopkins S; Chand M; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Apr; 386(16):1532-1546. PubMed ID: 35249272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
    Wahid M; Jawed A; Mandal RK; Areeshi MY; El-Shall NA; Mohapatra RK; Tuli HS; Dhama K; Pellicano R; Fagoonee S; Haque S
    Minerva Med; 2023 Oct; 114(5):683-697. PubMed ID: 37293890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    El-Shesheny R; El Taweel A; Gomaa MR; Roshdy WH; Kandeil A; Webby RJ; Kayali G; Ali MA
    Vaccine; 2022 Jul; 40(32):4303-4306. PubMed ID: 35697574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
    Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
    BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2.
    Ali F; Alom S; Shakya A; Ghosh SK; Singh UP; Bhat HR
    Arch Pharm (Weinheim); 2022 May; 355(5):e2100360. PubMed ID: 35244237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
    Wu N; Joyal-Desmarais K; Ribeiro PAB; Vieira AM; Stojanovic J; Sanuade C; Yip D; Bacon SL
    Lancet Respir Med; 2023 May; 11(5):439-452. PubMed ID: 36780914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
    Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: vaccines, efficacy and effects on variants.
    Rudan I; Adeloye D; Sheikh A
    Curr Opin Pulm Med; 2022 May; 28(3):180-191. PubMed ID: 35200162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.
    Kakkassery H; Carpenter E; Patten PEM; Irshad S
    Trends Mol Med; 2022 Dec; 28(12):1082-1099. PubMed ID: 35999131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19: From emerging variants to vaccination.
    Senevirathne TH; Wekking D; Swain JWR; Solinas C; De Silva P
    Cytokine Growth Factor Rev; 2024 Apr; 76():127-141. PubMed ID: 38135574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Feikin DR; Higdon MM; Abu-Raddad LJ; Andrews N; Araos R; Goldberg Y; Groome MJ; Huppert A; O'Brien KL; Smith PG; Wilder-Smith A; Zeger S; Deloria Knoll M; Patel MK
    Lancet; 2022 Mar; 399(10328):924-944. PubMed ID: 35202601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.